Millipore Corporation 

(Public, NYSE:MIL)   Watch this stock   
Find more results for MIL
Nov 5, 2009
Q3 2009 Earnings Conference Call - Webcast
Nov 5, 2009
Q3 2009 Earnings Release
Sep 9, 2009
Thomas Weisel Partners Healthcare Conference - Webcast
More events from AOL Finance »    

Key stats and ratios

Q4 (Oct '09) 2008
Net profit margin 9.76% 9.32%
Operating margin 15.33% 14.57%
EBITD margin - 22.83%
Return on average assets 5.73% 5.40%
Return on average equity 10.89% 12.08%
Employees 5,900 -

Address

290 Concord Road
Billerica, MA 01821
United States - Map
+1-978-7154321 (Phone)
+1-781-5333110 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
About Company - Wikipedia

Millipore Corporation discussed on blogs

Ranking 700+ Mid-Cap Stocks by Upside Potential - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - 4 hours ago
Millipore - Investor Relations - Press Releases - Millipore Product News - Sep 5, 2007

Millipore Corporation discussions

  View all discussions »

Description

Millipore Corporation (Millipore) is a life science company. The Company provides products and services that help its academic, biotechnology and pharmaceutical customers advance their research, development and production. Its products and services help customers increase their speed and improve their consistency while saving costs in laboratory applications and in biopharmaceutical manufacturing. Its products help biotechnology and pharmaceutical companies manufacture therapeutics, particularly biologic drugs, such as monoclonal antibodies, recombinant proteins and vaccines. Millipore’s products ensure the purity and safety of biologic drugs by removing contaminants, such as viruses and bacteria and by providing tests. The Company acquired Guava Technologies on February 20, 2009. In August 2009, the Company acquired BioAnaLab, a European-based services provider that specializes in the analysis of biologic drugs and vaccines.

Officers and directors

Martin D. Madaus Ph.D.
Chairman of the Board, President, Chief Executive Officer
Age: 49
Bio & Compensation - Reuters
Charles F. Wagner Jr.
Chief Financial Officer, Vice President
Age: 40
Bio & Compensation - Reuters
Peter C. Kershaw
Vice President - Global Operations
Age: 55
Bio & Compensation - Reuters
Dennis W. Harris
Vice President, Chief Scientific Officer
Age: 52
Bio & Compensation - Reuters
Jeffrey Rudin
Vice President, General Counsel, Secretary
Age: 57
Bio & Compensation - Reuters
Bruce J. Bonnevier
Vice President - Global Human Resources
Age: 50
Bio & Compensation - Reuters
Jean-Paul Mangeolle
Vice President, President - Bioprocess Division
Age: 47
Bio & Compensation - Reuters
Geoffrey F. Ide
Vice President, Millipore International
Age: 55
Bio & Compensation - Reuters
Jonathan DiVincenzo
Vice President, President - Bioscience Division
Age: 43
Bio & Compensation - Reuters
Ram Ramakrishnan
Vice President - Strategy and Corporate Development
Bio & Compensation - Reuters